Online Supplement – Table 1. Selection of patients receiving apixaban or warfarin as outpatient therapy for VTE

	Humana [n (%)]			MarketScan [n (%)]			Optum [n (%)]			PharMetrics [n (%)]			Total Population [n (%)]		
Inclusion/Exclusion Criteria	Apixaban	Warfarin	Total	Apixaban	Warfarin	Total	Apixaban	Warfarin	Total	Apixaban	Warfarin	Total	Apixaban	Warfarin	Total
Selection of Subjects															
Inclusion criteria:															
Aged ≥18 years with diagnosis of VTE from September 1, 2014 to June 30, 2017:	---	---	221,647 (100.0%)	---	---	380,035 (100.0%)	---	---	320,098 (100.0%)	---	---	463,551 (100.0%)	---	---	1,385,331 (100.0%)
Setting:															
Acute-Care Inpatient	---	---	85,120 (38.4%)	---	---	74,195 (19.5%)	---	---	108,014 (33.7%)	---	---	114,683 (24.7%)	---	---	382,012 (27.6%)
Ambulatory Care	---	---	136,527 (61.6%)	---	---	305,840 (80.5%)	---	---	212,084 (66.3%)	---	---	348,868 (75.3%)	---	---	1,003,319 (72.4%)
Diagnosis:															
Diagnosis of PE (with or without DVT)	---	---	66,428 (30.0%)	---	---	110,436 (29.1%)	---	---	96,415 (30.1%)	---	---	132,802 (28.6%)	---	---	406,081 (29.3%)
Diagnosis of DVT Only	---	---	155,219 (70.0%)	---	---	269,599 (70.9%)	---	---	223,683 (69.9%)	---	---	330,749 (71.4%)	---	---	979,250 (70.7%)
Presumed aetiology:															
Provoked	---	---	67,668 (30.5%)	---	---	94,836 (25.0%)	---	---	79,994 (25.0%)	---	---	104,538 (22.6%)	---	---	347,036 (25.1%)
Unprovoked	---	---	153,979 (69.5%)	---	---	285,199 (75.0%)	---	---	240,104 (75.0%)	---	---	359,013 (77.4%)	---	---	1,038,295 (74.9%)
plus ≥1 outpatient pharmacy claim for apixaban or warfarin during 30-day period following the index encounter	10,034 (4.5%)	40,709 (18.4%)	50,743 (22.9%)	11,245 (3.0%)	62,640 (16.5%)	73,885 (19.4%)	10,987 (3.4%)	57,337 (17.9%)	68,324 (21.3%)	15,973 (3.4%)	76,117 (16.4%)	92,090 (19.9%)	48,239 (3.5%)	236,803 (17.1%)	285,042 (20.6%)
plus health benefits for ≥6 months prior to index therapy	8,613 (3.9%)	32,486 (14.7%)	41,099 (18.5%)	10,030 (2.6%)	55,340 (14.6%)	65,370 (17.2%)	7,899 (2.5%)	41,755 (13.0%)	49,654 (15.5%)	11,732 (2.5%)	59,923 (12.9%)	71,655 (15.5%)	38,274 (2.8%)	189,504 (13.7%)	227,778 (16.4%)
Exclusion criteria:															
plus no claims for conditions/procedures:															
No claims for atrial fibrillation/flutter during 6-month period prior to index therapy	6,229 (2.8%)	23,593 (10.6%)	29,822 (13.5%)	8,963 (2.4%)	48,547 (12.8%)	57,510 (15.1%)	6,673 (2.1%)	33,919 (10.6%)	40,592 (12.7%)	10,496 (2.3%)	54,109 (11.7%)	64,605 (13.9%)	32,361 (2.3%)	160,168 (11.6%)	192,529 (13.9%)
No claims for chemotherapy/radiation therapy for malignancy* during 6-month period prior to index therapy	5,710 (2.6%)	22,175 (10.0%)	27,885 (12.6%)	8,392 (2.2%)	46,118 (12.1%)	54,510 (14.3%)	6,242 (2.0%)	32,162 (10.0%)	38,404 (12.0%)	9,923 (2.1%)	51,960 (11.2%)	61,883 (13.3%)	30,267 (2.2%)	152,415 (11.0%)	182,682 (13.2%)
No claims for malignancy* during 90-day period prior to index therapy	4,990 (2.3%)	19,724 (8.9%)	24,714 (11.2%)	7,624 (2.0%)	41,935 (11.0%)	49,559 (13.0%)	5,637 (1.8%)	29,036 (9.1%)	34,673 (10.8%)	9,245 (2.0%)	48,804 (10.5%)	58,049 (12.5%)	27,496 (2.0%)	139,499 (10.1%)	166,995 (12.1%)
No claims for IVCF during study period	4,852 (2.2%)	19,068 (8.6%)	23,920 (10.8%)	7,357 (1.9%)	40,503 (10.7%)	47,860 (12.6%)	5,533 (1.7%)	28,148 (8.8%)	33,681 (10.5%)	9,034 (1.9%)	47,399 (10.2%)	56,433 (12.2%)	26,776 (1.9%)	135,118 (9.8%)	161,894 (11.7%)
No claims for pregnancy during study period	4,830 (2.2%)	18,888 (8.5%)	23,718 (10.7%)	7,232 (1.9%)	39,707 (10.4%)	46,939 (12.4%)	5,478 (1.7%)	27,753 (8.7%)	33,231 (10.4%)	8,221 (1.8%)	41,674 (9.0%)	49,895 (10.8%)	25,761 (1.9%)	128,022 (9.2%)	153,783 (11.1%)
plus no evidence of any OAC/PAC use during 30-day period prior to index encounter	4,637 (2.1%)	18,011 (8.1%)	22,648 (10.2%)	6,975 (1.8%)	37,564 (9.9%)	44,539 (11.7%)	5,328 (1.7%)	26,416 (8.3%)	31,744 (9.9%)	7,931 (1.7%)	39,467 (8.5%)	47,398 (10.2%)	24,871 (1.8%)	121,458 (8.8%)	146,329 (10.6%)
plus no evidence of any OAC/PAC use during 6-month period prior to index encounter except prophylactic use**	4,636 (2.1%)	17,996 (8.1%)	22,632 (10.2%)	6,968 (1.8%)	37,516 (9.9%)	44,484 (11.7%)	5,319 (1.7%)	26,371 (8.2%)	31,690 (9.9%)	7,921 (1.7%)	39,409 (8.5%)	47,330 (10.2%)	24,844 (1.8%)	121,292 (8.8%)	146,136 (10.5%)
plus no evidence of receipt of >1 OAC during period between index encounter and index therapy initiation[†]	4,614 (2.1%)	17,957 (8.1%)	22,571 (10.2%)	6,892 (1.8%)	37,373 (9.8%)	44,265 (11.6%)	5,285 (1.7%)	26,262 (8.2%)	31,547 (9.9%)	7,870 (1.7%)	39,292 (8.5%)	47,162 (10.2%)	24,661 (1.8%)	120,884 (8.7%)	145,545 (10.5%)
plus no claims for VTE during 6-month period prior to index encounter	4,566 (2.1%)	12,443 (5.6%)	17,009 (7.7%)	6,656 (1.8%)	23,131 (6.1%)	29,787 (7.8%)	5,247 (1.6%)	18,657 (5.8%)	23,904 (7.5%)	7,820 (1.7%)	28,859 (6.2%)	36,679 (7.9%)	24,289 (1.8%)	83,090 (6.0%)	107,379 (7.8%)
plus evidence of PAC within +/- 14 days of warfarin initiation (ambulatory care only)	4,566 (2.1%)	7,853 (3.5%)	12,419 (5.6%)	6,656 (1.8%)	10,623 (2.8%)	17,279 (4.5%)	5,247 (1.6%)	12,466 (3.9%)	17,713 (5.5%)	7,820 (1.7%)	12,681 (2.7%)	20,501 (4.4%)	24,289 (1.8%)	43,623 (3.1%)	67,912 (4.9%)
plus no claims for bleeding during 6-month period prior to index therapy	3,719 (1.7%)	5,949 (2.7%)	9,668 (4.4%)	5,748 (1.5%)	9,069 (2.4%)	14,817 (3.9%)	4,419 (1.4%)	9,956 (3.1%)	14,375 (4.5%)	6,675 (1.4%)	10,106 (2.2%)	16,781 (3.6%)	20,561 (1.5%)	35,080 (2.5%)	55,641 (4.0%)
Study Population															
All Patients	**3,719 (1.7%)**	**5,949 (2.7%)**	**9,668 (4.4%)**	**5,748 (1.5%)**	**9,069 (2.4%)**	**14,817 (3.9%)**	**4,419 (1.4%)**	**9,956 (3.1%)**	**14,375 (4.5%)**	**6,675 (1.4%)**	**10,106 (2.2%)**	**16,781 (3.6%)**	**20,561 (1.5%)**	**35,080 (2.5%)**	**55,641 (4.0%)**
Matched Patients	**3,318 (1.5%)**	**3,318 (1.5%)**	**6,636 (3.0%)**	**4,356 (1.1%)**	**4,356 (1.1%)**	**8,712 (2.3%)**	**4,243 (1.3%)**	**4,243 (1.3%)**	**8,486 (2.7%)**	**5,961 (1.3%)**	**5,961 (1.3%)**	**11,922 (2.6%)**	**17,878 (1.3%)**	**17,878 (1.3%)**	**35,756 (2.6%)**

DVT: Deep vein thrombosis; IVCF: Inferior vena cava filter; OAC: Oral anticoagulants; PAC: Parenteral anticoagulants; PE: Pulmonary embolism; VTE: Venous thromboembolism

*Other than non-melanoma skin cancer

**Prophylactic use of OAC/PAC will be determined based on duration and timing of use (See Appendix B)

[†]Including date of index encounter and date of index therapy initiation